Tarek . I . Kakhia
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
LD5655.V855 1924.M377.Pdf
A STUDY OF BACILLUS AROIDEAE 'l'OWNSEND, THE CAUSE OF A SOFT ROT OF TOMATO, AN:) B. CAROTOVORUS JONES. A thesis 811.bmitted as partial requirement for the degree of Master of Science in Botany by A.B.Massey Reprinted from PHYT0PATH0L0GY, Vol. XIV, October, 1924. A STUDY OF BACILLUS AROIDEAE, TOWNSEND, THE CAUSE OF A SOFT ROT OF TOMATO, AND B. CAROTOVORUS JONES A. B. MASSEY! \Vl'l'll Tlll:EE FIGURES IN THE TEXT INTRODUCTION In the summer of 1918, at Blacksburg, Virginia, there developed a con- siderable amount of a soft rot of tomatoes. This occurre<l in experimental plots which were designated to study the control of septoria leaf blight, and the soft rot of the fruit developed into an important factor. I~ describing these experiments Fromme (2) states: "Practically all of the unsoundness of the fruit was caused by bacterial soft rot, a disease which is exceedingly common and often very destructive in tomato fields in Vir- ginia." Isolations from diseased fruits made by S. A. Wingard (15) proved a bacterium to be the causative agent. Its growth in pure culture resembled that of the group of bacteria which causes soft rots of plants but it could not be readily as!ligned to any of the describe<l species of this group. There has been only casual mention of a bacterial soft rot of tomato in literature, and the distinguishing features of the organisms which might be responsible have not been as sharply defined as is desirable. It was decided, therefore, to un<lcrtake comparative studies of the organism in question together with some of the non-chromogenic soft rot forms. -
United States Patent [19] [11] 15 Re. 30,811 Dykstra Et A1
United States Patent [19] [11] 15 Re. 30,811 Dykstra et a1. [45] Reissued Dec. 1, 1981 [54] SUBSTITUTED PIPERIDINES 2,780,577 2/1957 Phillips et a]. .................. .. 424/267 THERAPEUTIC PROCESS AND 3,192,213 1/1965 Krapcho . .. 260/253 COMPOSITIONS 3,789,072 1/1974 Bernstein ...... .. 260/557 D 3,931,195 1/1976 Dykstra et a1. .............. .. 260/293.58 [75] Inventors: Stanley J. Dykstra; Joseph L. OTHER PUBLICATIONS Minielli, both of Evansville, Ind. 73 A. - ._ Mead J hnson 81 C a Lawson, J. Pharm. Ex p . Thera p ., 160, pp . 21-31 (1968). [ 1 ‘Slgnee Evansv?le in mm’ ‘W’ Krapcho et al., J. Med. Chem, 6, p. 219 (1963). ' Krapcho et al., J. Med. Chem, 7, pp. 376-377 (1964). [2!] Appl- NW 98.008 Krapcho et 31., .1. Med. Chem, 9, pp. 809-812 (1966). [22] Filed. No“ 28, 1979 Krapcho et al., J. Med. Chem, 12, pp. 164-166 (1969). Phillips, J. Am. Chem. Soc., 72, pp. 1850-1852 (1950). Related US. Patent Documents Primary Examiner—Stanley J. Friedman Reissue of. Attorney, Agent, or Firm-Robert H. Uloth; Robert E. [64] Patent NO.I 4,064,254 Camha" Issued: Dec. 20, 1977 [57] ABSTRACT F531:A 1. N 0 .: 0cL734,583 21 1976 The compounds are of the heterocycltc, class of 2 v _ ’ phenethylpiperidines having an amido substituent in the U-5- APPl1cat1°I151 ortho position of the phenethyl moiety. Substituents in 160] Dlvisio" 0151?’ NO- 620-207’ Ocl- 3» 19751 Pa" N°~ the ortho position include formamido, benzamido, cin 4‘00Oé143' wh‘ch '5 agd‘wls‘gn 025:", No- 384'34l' Jul" namamido, 2-thiophenecarboxamido, alkanesul 31' 1. -
Inhaled Nitric Oxide Therapy in Adults Benedict C Creagh-Brown, Mark JD Griffiths and Timothy W Evans
Available online http://ccforum.com/content/13/3/212 Review Bench-to-bedside review: Inhaled nitric oxide therapy in adults Benedict C Creagh-Brown, Mark JD Griffiths and Timothy W Evans Unit of Critical Care, Faculty of Medicine, Imperial College, London, UK and Adult Intensive Care Unit, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK Corresponding author: Timothy W Evans, [email protected] Published: 29 May 2009 Critical Care 2009, 13:212 (doi:10.1186/cc7734) This article is online at http://ccforum.com/content/13/3/221 © 2009 BioMed Central Ltd Abstract Administration of inhaled nitric oxide to adults Nitric oxide (NO) is an endogenous mediator of vascular tone and The licensed indication of iNO is restricted to persistent host defence. Inhaled nitric oxide (iNO) results in preferential pulmonary hypertension in neonates, yet most iNO is pulmonary vasodilatation and lowers pulmonary vascular resis- administered for unlicensed indications. Pharmaceutical iNO tance. The route of administration delivers NO selectively to is available at a very high cost, and in light of this and ventilated lung units so that its effect augments that of hypoxic concerns over potential adverse effects of iNO, international pulmonary vasoconstriction and improves oxygenation. This guidelines have been developed. An advisory board under the ‘Bench-to-bedside’ review focuses on the mechanisms of action of iNO and its clinical applications, with emphasis on acute lung injury auspices of the European Society of Intensive Care Medicine and the acute respiratory distress syndrome. Developments in our and the European Association of Cardiothoracic Anaes- understanding of the cellular and molecular actions of NO may thesiologists published its recommendations in 2005 [1]. -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
Derivatives of Carboxylic Acid
Derivatives of Carboxylic Acid acid chloride carboxylate nitrile amide acid anhydride ester Nomenclature of Acid Halides IUPAC: alkanoic acid → alkanoyl halide Common: alkanic acid → alkanyl halide I: 3-aminopropanoyl chloride I: 4-nitropentanoyl chloride c: b-aminopropionyl chloride c: g-nitrovaleryl chloride I: hexanedioyl chloride c: adipoyl chloride Rings: (IUPAC only): ringcarbonyl halide I: benzenecarbonyl bromide I: 3-cylcopentenecarbonyl chloride c: benzoyl bromide Nomenclature of Acid Anhydrides Acid anhydrides are prepared by dehydrating carboxylic acids acetic anhydride ethanoic acid ethanoic anhydride I: benzenecarboxylic anhydride I: butanedioic acid I: butanedioic anhydride c: benzoic andhydride c: succinic acid c: succinic anhydride Some unsymmetrical anhydrides I: ethanoic methanoic I: benzoic methanoic anhydride anhydride I: cis-butenedioic c: benzoic formic anhydride anhydride c: acetic formic anhydride Nomenclature of Esters Esters occur when carboxylic acids react with alcohols I: phenyl methanoate I: t-butyl benzenecarboxylate I: methyl ethanoate c: phenyl formate c: methyl acetate c: t-butyl benzoate I: isobutyl I: cyclobutyl 2- I: dimethyl ethanedioate cyclobutanecarboxylate methylpropanoate c: cyclobutyl a- c: dimethyl oxalate c: none methylpropionate Cyclic Esters Reaction of -OH and -COOH on same molecule produces a cyclic ester, lactone. To name, add word lactone to the IUPAC acid name or replace the -ic acid of common name with -olactone. 4-hydroxy-2-methylpentanoic acid lactone -methyl- -valerolactone Amides Product of the reaction of a carboxylic acid and ammonia or an amine. Not basic because the lone pair on nitrogen is delocalized by resonance. Classes of Amides 1 amide has one C-N bond (two N-H). 2 amide or N-substituted amide has two C-N bonds (one N-H). -
Unit 15 Monocarboxylic and Sulphonjc Acids
UNIT 15 MONOCARBOXYLIC AND SULPHONJC ACIDS Structure Introduction Objectives Carboxylic Acids Preparation of Monocarboxylic Acids physical Properties of ~onocarbox~licAcids Spectral Properties of Carboxylic Acids Reactions of Carboxylic Acids Sulphonic Acids Preparation of Benzenesulphonic acid Reactions of Benzenesulphonic acid Industrial Uses of Carboxylic and Sulphonic Acids Laboratory Detection of Carboxylic and Sulphonic Acids Summary Terminal Questions Answers 15.1 INTRODUCTION 0 I Carboxylic acids are the compounds which contain the carboxy (-COH) functional 0 I1 group and can be represented either as RCOH or as RCOOH. The carboxylic acids not only form an important class of organic compounds but are also the parent compounds of a large group of compounds called the functional derivatives of carboxylic acids which can be further classified as acid halides, acid anhydrides, acid .amides and esters. These classes of compounds \kill be discussed in Unit 17. Carboxylic acids also play an important role in various biological processes. In Unit 16, you will study about some such acids ..Besides carboxylic acids, there is another important class of organic acids, called sulphonic adds. The sulphonic acids are the compounds which contain a S03H group, called the sulphonic acid soup. Sulphonic acids are organic acids related to sulphuric acid. Sulphonic acids and carboxylic acids are closely related in their chemistry. Therefore, in this unit, we will first study the chemistry of carboxylic acids and then that of the sulphonic acids. Objectives -
Chemical Specificity in Short-Chain Fatty Acids and Their Analogues in Increasing Osmotic Fragility in Rat Erythrocytes in Vitro
Chemical specificity in short-chain fatty acids and their analogues in increasing osmotic fragility in rat erythrocytes in Title vitro. Author(s) Mineo, Hitoshi; Hara, Hiroshi Biochimica et Biophysica Acta (BBA) - Biomembranes, 1768(6), 1448-1453 Citation https://doi.org/10.1016/j.bbamem.2007.02.008 Issue Date 2007-06 Doc URL http://hdl.handle.net/2115/28208 Type article (author version) File Information BBA1768-6.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP 1 1 Chemical specificity in short-chain fatty acids and their analogues in increasing osmotic 2 fragility in rat erythrocytes in vitro 3 4 Hitoshi Mineo, Hiroshi Hara* 5 6 Division of Applied Bioscience, Graduate School of Agriculture, Hokkaido University, 7 Hokkaido 060-8589, Japan 8 9 10 *Corresponding author. 11 Hiroshi HARA Ph.D. 12 Division of Applied Bioscience, 13 Graduate School of Agriculture, 14 Hokkaido University, 15 Kita-9, Nishi-9, Sapporo, 16 Hokkaido 060-8589, 17 Tel.: +81-11-706-3352; 18 fax: +81-11-706-2504. 19 E-mail address: [email protected] 20 21 22 23 24 25 2 1 Abstract 2 3 We examined the role of the chemical specificity of short-chain fatty acids 4 (SCFAs) and their derivatives in increasing osmotic fragility (OF) in rat red blood cells 5 (RBCs). Except for formic acid, normal SCFAs with 2 to 8 carbons increased the OF in 6 rat RBCs with increasing number of hydrocarbons in a dose-dependent manner. 7 Replacement of the carboxylic group with sulfonic group inhibited, but did not abolish, 8 the SCFA-mediated increase in OF. -
Leaf Variegation in Caladium Steudneriifolium (Araceae): a Case of Mimicry?
Evol Ecol (2009) 23:503–512 DOI 10.1007/s10682-008-9248-2 ORIGINAL PAPER Leaf variegation in Caladium steudneriifolium (Araceae): a case of mimicry? Ulf Soltau Æ Stefan Do¨tterl Æ Sigrid Liede-Schumann Received: 27 November 2007 / Accepted: 25 February 2008 / Published online: 6 March 2008 Ó Springer Science+Business Media B.V. 2008 Abstract The leaves of Caladium steudneriifolium (Araceae) of the understorey of a submontane rainforest in the Podocarpus National Park (South East Ecuador, 1,060 m a.s.l.) are plain green or patterned with whitish variegation. Of the 3,413 individual leaves randomly chosen and examined in April 2003, two-thirds were plain green, whereas one third were variegated (i.e., whitish due to absence of chloroplasts). Leaves of both morphs are frequently attacked by mining moth caterpillars. Our BLAST analysis based on Cytochrome-c-Oxidase-subunit-1 sequences suggests that the moth is possibly a member of the Pyraloidea or another microlepidopteran group. It was observed that the variegated leaf zones strongly resemble recent damages caused by mining larvae and therefore may mimic an attack by moth larvae. Infestation was significantly 4–12 times higher for green leaves than for variegated leaves. To test the hypothesis that variegation can be interpreted as mimicry to deter ovipositing moths, we first ruled out the possibility that variegation is a function of canopy density (i.e., that the moths might be attracted or deterred by factors unrelated to the plant). Then plain green leaves were artificially variegated and the number of mining larvae counted after 3 months. -
Aldrich Raman
Aldrich Raman Library Listing – 14,033 spectra This library represents the most comprehensive collection of FT-Raman spectral references available. It contains many common chemicals found in the Aldrich Handbook of Fine Chemicals. To create the Aldrich Raman Condensed Phase Library, 14,033 compounds found in the Aldrich Collection of FT-IR Spectra Edition II Library were excited with an Nd:YVO4 laser (1064 nm) using laser powers between 400 - 600 mW, measured at the sample. A Thermo FT-Raman spectrometer (with a Ge detector) was used to collect the Raman spectra. The spectra were saved in Raman Shift format. Aldrich Raman Index Compound Name Index Compound Name 4803 ((1R)-(ENDO,ANTI))-(+)-3- 4246 (+)-3-ISOPROPYL-7A- BROMOCAMPHOR-8- SULFONIC METHYLTETRAHYDRO- ACID, AMMONIUM SALT PYRROLO(2,1-B)OXAZOL-5(6H)- 2207 ((1R)-ENDO)-(+)-3- ONE, BROMOCAMPHOR, 98% 12568 (+)-4-CHOLESTEN-3-ONE, 98% 4804 ((1S)-(ENDO,ANTI))-(-)-3- 3774 (+)-5,6-O-CYCLOHEXYLIDENE-L- BROMOCAMPHOR-8- SULFONIC ASCORBIC ACID, 98% ACID, AMMONIUM SALT 11632 (+)-5-BROMO-2'-DEOXYURIDINE, 2208 ((1S)-ENDO)-(-)-3- 97% BROMOCAMPHOR, 98% 11634 (+)-5-FLUORODEOXYURIDINE, 769 ((1S)-ENDO)-(-)-BORNEOL, 99% 98+% 13454 ((2S,3S)-(+)- 11633 (+)-5-IODO-2'-DEOXYURIDINE, 98% BIS(DIPHENYLPHOSPHINO)- 4228 (+)-6-AMINOPENICILLANIC ACID, BUTANE)(N3-ALLYL)PD(II) CL04, 96% 97 8167 (+)-6-METHOXY-ALPHA-METHYL- 10297 ((3- 2- NAPHTHALENEACETIC ACID, DIMETHYLAMINO)PROPYL)TRIPH 98% ENYL- PHOSPHONIUM BROMIDE, 12586 (+)-ANDROSTA-1,4-DIENE-3,17- 99% DIONE, 98% 13458 ((R)-(+)-2,2'- 963 (+)-ARABINOGALACTAN BIS(DIPHENYLPHOSPHINO)-1,1'- -
(12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO). -
Supporting Document 1
Supporting document 1 Risk and Technical Assessment Report – Application A1103 Citric & Lactic Acids as Food Additives in Beer and related products Executive Summary FSANZ received an Application from DB Breweries Limited seeking to amend Standard 1.3.1 – Food Additives of the Australia New Zealand Food Standards Code (the Code) to permit the addition of citric and lactic acids as food additives in beer. Within Standard 1.3.1, this permission would apply to the food category 14.2.1 - Beer and related products. Citric and lactic acids are currently permitted as food additives in a large range of foods at levels consistent with Good Manufacturing Practice (GMP). For the proposed use of citric and lactic acids in beer and related products, this Application also requests GMP permission. The food technology assessment concluded that certain types of beers exhibit improved flavour profiles due to pH reduction achieved by the addition of citric and lactic acids. Maximum levels of addition are expected to be approximately 3 g per litre of beer (total of citric acid plus lactic acid). Citric acid and lactic acid are substances of very low toxicity. Citric acid occurs in many foods, with levels of approximately 10 and 50 g/L in orange juice and lemon juice, respectively. Lactic acid levels are highest in foods produced by fermentation, with levels of approximately 10 g/kg reported for cheese and yogurt. The Joint FAO/WHO Expert Committee on Food Additives (JECFA) concluded that establishment of an Acceptable Daily Intake (ADI) expressed in numerical terms was unnecessary for either substance. -
Used at Rocky Flats
. TASK 1 REPORT (Rl) IDENTIFICATION OF CHEMICALS AND RADIONUCLIDES USED AT ROCKY FLATS I PROJECT BACKGROUND ChemRisk is conducting a Rocky Flats Toxicologic Review and Dose Reconstruction study for The Colorado Department of Health. The two year study will be completed by the fall of 1992. The ChemRisk study is composed of twelve tasks that represent the first phase of an independent investigation of off-site health risks associated with the operation of the Rocky Flats nuclear weapons plant northwest of Denver. The first eight tasks address the collection of historic information on operations and releases and a detailed dose reconstruction analysis. Tasks 9 through 12 address the compilation of information and communication of the results of the study. Task 1 will involve the creation of an inventory of chemicals and radionuclides that have been present at Rocky Flats. Using this inventory, chemicals and radionuclides of concern will be selected under Task 2, based on such factors as the relative toxicity of the materials, quantities used, how the materials might have been released into the environment, and the likelihood for transport of the materials off-site. An historical activities profile of the plant will be constructed under Task 3. Tasks 4, 5, and 6 will address the identification of where in the facility activities took place, how much of the materials of concern were released to the environment, and where these materials went after the releases. Task 7 addresses historic land-use in the vicinity of the plant and the location of off-site populations potentially affected by releases from Rocky Flats.